The effect of Eldecalcitol for glucocorticoid induced osteoporosis patients who are not recommended bisphosphonates therapy

The effect of Eldecalcitol for glucocorticoid induced osteoporosis patients who are not recommended bisphosphonates therapy - The effect of Eldecalcitol for glucocorticoid induced osteoporosis patients who are not recommended bisphosphonates therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009589

Enrollment

Registered

2012-12-20

Start date

2012-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glucocorticoid induced osteoporosis

Interventions

Eldecalcitol (0.75mcg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who are using or planning to use oral glucocorticoids for more 3 months or longer and who are not recommended bisphosphonates therapy. 2. Patients with informed of consent.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindication for Eldecalcitol treatments 2. Patients who are inappropriate for this study by physicians.

Design outcomes

Primary

Measure	Time frame
Change from baseline to 12 months in lumbar spine BMD	—

Countries

Japan

Contacts

Public ContactGoh Tsuji

Shinko Hospital Department of Rheumatic Disease

tsuji_goh@shinkohp.or.jp078-261-6711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026